This arrangement is not a classic partnership , as Amarantus is maintaining all intellectual property rights to current and future versions of LymPro at the current time. This is a services agreement that gets the ball rolling on the CLIA process as we make progress on our ongoing LP-002 clinical study and puts Icon in a sub-contractor relationship with respect to LymPro. -

If it weren't a partnership at all, he would have said, this is not a partnership, period/full stop.

See more at: http://www.thechairmansblog.com/amarantus-bio...B2pvM.dpuf